Journal of Urgent Care Medicine

Studies Find No Increased Risk of Suicide With Semaglutide

The glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide (Wegovy, Ozempic) was found to demonstrate no increased risk of suicidal ideation in patients with obesity or type 2 diabetes, according to retrospective analyses of electronic health records examining these patient populations, published in Nature Medicine. Researchers’ analysis of 240,618 patients who were overweight/obese showed that those taking semaglutide had a significantly lower risk (0.11%) of suicidal ideation compared with those using non-GLP-1 anti-obesity medications (0.43%). In …

Patients More Likely to Stick With Semaglutide Treatment

Patients taking the GLP-1 weight loss drug semaglutide were 3 times more likely to maintain adherence to their medication regimens a year later when compared to other drug options, according to a Cleveland Clinic study. As described in Obesity, researchers examined health records of 1,911 adults in two states and found 40% of semaglutide patients were still filling their prescriptions 12 months after the initiation of treatment. Patients using other anti-obesity drugs, such as orlistat, liraglutide, …

Urgent Care Services Rendered

UCA’S SURVEY COMMITTEE drew two important conclusions from its first industry-wide survey: urgent care is a growing industry nationwide, and those within the industry are hungry for benchmarking data. In each issue of JUCM, Developing Data will seek to fulfill that need. In this issue, a look at the breadth of services offered by respondents to the survey: